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INTRODUCTION
Ovarian tumors of borderline malignancy, borderline ovar-
ian tumors (BOT), constitute about 10-15% of all epithe-
lial ovarian malignancies (1). Radical surgery remains the
standard treatment for BOT. However, conservative treat-
ment might be considered in patients who want to preserve
their fertility because of the excellent prognosis reported (2,
3). Although spontaneous conceptions have been reported
after conservative surgery, some of these patients suffer from
infertility and require infertility treatment. Some BOT infer-
tile patients undergo assisted reproductive technologies
(ART) to improve their chances of pregnancy. 
The influence of infertility treatment on the development
of ovarian malignancies is a controversial topic. In a case-con-
trol study, it has been reported that a history of infertility
increases the overall risk of ovarian cancer (4). In addition,
there are reports suggesting an association between fertility
medication and BOT. However, the association between fer-
tility medication and invasive ovarian cancer is not conclu-
sive (5-7). It was suggested that high serum estradiol levels
during ovarian hyperstimulation might promote tumor
growth in BOT, especially in estrogen receptor expression-
positive cases (8, 9). Therefore, the potential risk associated
with infertility and treatment must be considered for infer-
tile patients after conservative treatment for BOT. 
In early-stage BOT, it has been possible to consider ART
after conservative treatment since a multicenter study that
reported 16 BOT patients who had undergone in vitro fer-
tilization (IVF) after conservative treatment (10). Fasouliotis
et al. reported that the overall success rates of IVF were sat-
isfactory for this group of patients, suggesting no known
negative impact of prior BOT on pregnancy rates after IVF
(11). However, for advanced-stage BOT the published reports
are limited to case reports (12-14). Therefore, for patients
with advanced BOT the safety of ART after conservative
treatment remains anecdotal.
The purpose of this study was to evaluate the outcomes of
COH-IVF in infertile patients after conservative treatment
for BOT.
MATERIALS AND METHODS
Patients
A retrospective review of IVF records from January 1999
to July 2005 revealed 10 attempted IVF cycles in five patients
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Outcomes of Controlled Ovarian Hyperstimulation/In Vitro Fertilization
for Infertile Patients with Borderline Ovarian Tumor after Conservative
Treatment 
To evaluate the outcomes of controlled ovarian hyperstimulation (COH)-in vitro
fertilization (IVF) such as clinical pregnancy rate (CPR), implantation rate (IR) and
live birth rate (LBR) for infertile patients with borderline ovarian tumor (BOT) after
conservative treatment, 10 IVF cycles in five patients from January 1999 to July
2005 were analyzed. At the time of diagnosis with BOT, the mean age of patients
was 30.0 yr (range, 22-40). For 8 cycles out of 10 attempted IVF cycles, except for
2 cancellation cycles, the mean number of oocytes retrieved was 5.6 (range, 2-16)
with a mean fertilization rate of 74.4%. The CPR, IR, and LBR were 50.0% (4/8
cycles), 31.6% (6/19) and 50.0% (4/8 cycles) respectively. The mean follow-up
period after COH-IVF initiation was 29.6 (range, 14-61) months. A gynecological
oncologist followed all patients every 3 months during the first year and every 6
months thereafter. There was no recurrence during the follow-up period. Our results
suggest that COH-IVF may be acceptable for infertile patients with BOT, especial-
ly in patients with early-stage BOT after conservative treatment.
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who had been previously diagnosed with BOT and had had
conservative treatment to preserve fertility. BOT has the his-
tological characteristics of ovarian tumors: 1) epithelial pro-
liferation with the formation of a papillary configuration, 2)
demonstration of atypical epithelial activity, 3) mild or mod-
erate atypical nuclei, and 4) the absence of stromal invasion,
which distinguishes it from invasive carcinoma (Fig. 1). 
Conservative treatment is defined as preservation of the
uterus and at least a portion of one ovary. In cases where the
diagnosis of BOT was made intraoperatively, staging was
made according to the International Federation of Gynecol-
ogy and Obstetrics (FIGO) classification based on ipsilateral
pelvic and paraaortic lymph node dissections, peritoneal cy-
tology, omentectomy, and multiple peritoneal biopsies. After
conservative surgery, a gynecological oncologist followed all
patients every 3 months during the first year and thereafter
every 6 months with a physical examination, serum CA-125
levels and transvaginal ultrasound. The main outcome mea-
sures were pregnancy outcomes such as clinical pregnancy
rate (CPR), implantation rate (IR) and live birth rate (LBR)
after COH-IVF, and the recurrence of BOT during the fol-
low-up period. Approval from the institutional review board
was not obtained because this study was a retrospective case
observational study. 
COH-IVF and embryo transfer 
COH was performed with gonadotropin-releasing hor-
mone agonist (GnRH-a) long protocol or flare-up protocol
using human menopausal gonadotropin (Menogon
�, Fer-
ring, Germany) or recombinant follicle-stimulating hormone
(Puregon
�, Organon, Netherland). For the long protocol,
patients underwent pituitary desensitization with GnRH-a
(Suprefact
�, Hoechst, Germany) from the previous menstru-
al mid-luteal phase, and gonadotropins were administered
after pituitary down regulation and continued up to hCG
(Pregnyl
�, Organon, Netherland) administration. For the
flare-up protocol, GnRH-a was administered from the sec-
ond day of the menstrual cycle and gonadotropins were ad-
ministered from the third day of the menstrual cycle until
hCG administration. Oocyte retrieval was performed via the
transvaginal approach with sonographic guidance 36 hr after
10,000 IU of hCG administration. After oocyte retrieval,
oocyte maturation was evaluated under an inverted micro-
scope at ×400. The oocytes were incubated in human tubal
fluid (Irvine Scientific, Irvine, CA., U.S.A.) medium supple-
mented with 10% synthetic serum supplement (SSS; Irvine
Scientific) at 37℃, 5% CO2 in air. 
Embryos were transferred into the uterine cavity the third
day after oocyte retrieval. Pregnancy was determined by serum
-hCG levels above 5 mIU/mL 12 days after the oocyte ret-
rieval. Clinical pregnancy was defined as the presence of a
gestational sac on transvaginal ultrasound.
RESULTS
Ten IVF cycles were performed in five infertile patients
after conservative treatment for BOT. Two cycles out of 10
attempted IVF cycles were cancelled due to poor ovarian res-
Fig. 1. (A) Mucinous borderline tumor, endocervix-like type. It is composed of broad papillae covered with proliferating mucinous eitheli-
um. Proliferating tumor cells show tufting with mild to moderate cytologic atypia and neutrophils in their cytoplasm (inset). (B) Serous bor-
derline tumor. This tumor is composed of numerous papillae that are covered with serous epithelium showing proliferation with tufting and
cytologic atypia (left upper). This case reveals a few microinvasive foci (left lower) (H&E stain).
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ponse during COH.
Table 1 shows the demographics for the five patients and
the surgical findings. At the time of diagnosis with BOT,
the mean age of patients was 30.0 yr (range, 24-40), and four
out of five patients were nulliparous. In three patients (Patient
No. 2, 4, and 5) the diagnosis was made intraoperatively and
staged as Ia, Ia, and IIIc, respectively. In the remaining two
patients (Patients No. 1 and 3) the diagnosis was made post-
operatively without complete surgical staging. The micro-
scopic findings in three patients showed the mucinous type,
and the remaining two patients had the serous type. Patient
No. 5 had a few foci showing microinvasion (Fig. 1B).
Patient No. 2 underwent a right salpingoophorectomy;
disease recurrence occurred in the remaining ovary 9 yr after
the initial diagnosis and the recurrence showed a histology
and stage identical to the primary disease. The patient was
conservatively treated by cystectomy on the remaining ovary.
Patient No. 5 had right-side pelvic and paraaortic lymph
node dissections, peritoneal cytology, omentectomy, and mul-
tiple peritoneal biopsies; she was diagnosed with stage IIIc
disease. For the stromal microinvasion, the patient was treat-
ed with six cycles of taxol and cisplatin-based chemotherapy. 
At the time of the first IVF cycle the period of infertility
after conservative treatment ranged from 17 to 45 months
with a mean duration of 32.4 months. The indications for
IVF included severe endometriosis, male factor and unexpla-
ined infertility. Table 2 shows ART and pregnancy outcomes.
In patient No. 1, one cycle out of 2 attempted IVF cycles was
cancelled due to poor ovarian response. Because pregnancy
was not achieved with her own IVF cycles, oocyte donation
(OD) was performed due to the decreased ovarian reserve.
The patient was pregnant on the second OD cycle and deliv-
ered a healthy infant. Patient No. 3 had one cycle out of 4
attempted IVF cycles cancelled due to poor ovarian response.
Patient No. 4 had two pregnancies and delivered twice; the
first was after fresh embryo transfer and the second was after
frozen-thawed embryo transfer. 
In 10 attempted IVF cycles, two cycles were cancelled with
a 20.0% cycle cancellation rate. For eight IVF cycles, except
the cancelled cycles, the mean serum estradiol level on hCG
administration was 1,032.6 pg/mL (range, 200-2,380 pg/
mL). The mean number of retrieved oocytes was 5.6 (ran-
ge, 2-16), and the mean fertilization rate was 74.4% (range,
50.0-100.0%). The mean number of transferred embryos
was 2.4 (range, 1-4). The CPR, IR, and LBR were 50.0%
(4/8 cycles), 31.6% (6/19), and 50.0% (4/8 cycles), respec-
tively.
There was one case of disease recurrence after conservative
treatment; this recurrence developed before IVF treatment.
However, no recurrence was identified since the first IVF
cycle (Table 3). The follow-up period from initial diagnosis
to the first IVF cycle ranged from 5 to 127 months with a
mean duration of 33.0 months. Since the first IVF cycle, the
follow-up period ranged from 14 to 61 months with a mean
duration of 29.6 months. Patient No.2 had disease recur-
*, Combined with infracolic omentectomy and multiple biopsies; 
� , Com-
bined with infracolic omentectomy, Rt. pelvic & para-aortic lymph node
dissection and chemotherapy.
BOT, borderline ovarian tumor; RSO, Rt. Salpingo-oophorectomy; LSO,
Lt. Salpingo-oophorectomy; WR, Wedge resection.
Patient
Age 
(yr)
Parity Dx. Stage Histology Treatment
1 40 G1P1 Postop - Mucinous Cystectomy
2 24 G0P0 Intraop Ia Papillary serous RSO
33 G0P0 Intraop Ia Papillary serous Cystectomy
3 26 G0P0 Postop - Mucinous LSO+WR 
4 29 G0P0 Intraop Ia Mucinous RSO*
5 31 G0P0 Intraop IIIc Papillary serous  RSO+WR
�
microinvasion
Table 1. Clinical and pathological characteristics of BOT at
diagnosis
Patient
Infertility 
duration 
(mo)
Indication
IVF 
cycle 
No.
Age
(yr)
Basal
FSH
(mIU/mL)
E2 on
hCG
(pg/mL)
No. of
retrieved
oocytes
No.of
mature
oocytes
No. of 
transferred
embryos
Clinical
pregnancy 
1 38 Endometriosis IV 1 41 12 936 4 2 2 Non
2 41 20 260 OPU fail - - Cancel
3* 42 4 Non
4* 43 3 Single
2 17 Unexplained 1 33 3.5 653 4 4 2 Non
2 33 8.9 1,267 3 3 3 Single
3 18 Male factor 1 27 13 560 3 2 2 Non
2 27 10 320 2 1 1 Non
3 29 18 - - - - Cancel
4 29 8.2 200 2 1 1 Single
4 45 Tubal factor 1 30 1.7 1,945 16 10 4 Single
2
� 32 - - - - 2 Single
5 44 Unexplained 1 33 4.5 2,380 11 7 4 Twin
Table 2. ART and clinical pregnancy outcomes
*Oocyte donation cycles; 
� Frozen thawed embryo transfer. ART, assisted reproductive technologies; IVF, in vitro fertilization.IVF in Borderline Ovarian Tumor after Conservative Treatment  S137
rence 108 months after the initial diagnosis and 19 months
elapsed from the recurrence to the first IVF cycle. Patient
No.5 with stage IIIc disease had no recurrence identified by
exploration during cesarean section and continues to be fol-
lowed up by a gynecological oncologist.
DISCUSSION
Since the prognosis for BOT is excellent, patients of child-
bearing age can be treated with conservative surgery to pre-
serve fertility (2, 3). Unilateral adnexectomy is the optimal
treatment in patients whose diagnosis of BOT was made
intraoperatively; cystectomy can be considered in cases of
recurrence in the remaining ovary. Some patients are infer-
tile after conservative treatment and request ART in spite of
the potential risk associated with infertility treatment. A
history of infertility and the prior use of fertility medications
have been associated with the development of ovarian tumors.
Recent case control studies showed that infertility per se ele-
vates the overall risk of ovarian cancer (5). Rossing et al. re-
ported an increased risk of ovarian tumors, both invasive and
borderline, after the prolonged use (>12 cycles) of clomi-
phene citrate (15). Shushan et al. reported increased inci-
dence of epithelial ovarian tumors in patients with previous
human menopausal gonadotropin (hMG) treatment com-
pared to healthy controls (6).
However, the risk from ovarian hyperstimulation in pati-
ents treated for early stage BOT is low. Madelenat et al. re-
ported five pregnancies in 16 patients who subsequently
underwent IVF after conservative treatment for BOT and
found no case of relapse during the follow-up period, 46
months on average (10). Beiner et al. suggested that ART
might be considered after the diagnosis of BOT. Recurrence
occurred in 4 patients out of 7 who underwent IVF, two pa-
tients before and two patients after IVF treatment. All of
the recurrences had histology identical to the initial diagno-
sis, borderline malignancy (16). Fasouliotis et al. reported
17 IVF cycles in five patients after conservative BOT treat-
ment. A mean of 7.9 oocytes were retrieved with a 57.1%
fertilization rate, and a mean of 3.1 embryos were transferred.
The pregnancy rate per embryo transfer was 42.9% (17). To
date, there is no evidence in the literature to restrict the use
of ART in patients with early stage BOT after conservative
treatment. In our present study, the CPR and LBR for 7 IVF
cycles in patients with early stage BOT was 42.9% (3/7 cy-
cles) and 42.9% (3/7 cycle), respectively. The achieved preg-
nancy outcomes suggest that prior BOT, diagnosis and treat-
ment, have no perceptible negative impact on pregnancy
outcomes in COH-IVF. Therefore, COH-IVF can be safely
offered to the patients with early stage BOT.
However, there are few reports on the safety of COH-IVF
in cases of advanced stage BOT after conservative treatment.
Seidman and Kurman suggested that the existence of inva-
sion in a peritoneal implant is a poor prognostic factor in
patients with BOT with peritoneal implants; 16% had recur-
rence with a noninvasive implant, whereas 64% had recur-
rence with an invasive implant (18). Considering the poor
prognosis of BOT with invasive peritoneal implants, it seems
logical to propose conservative treatment only in patients
with BOT who do not have invasive implants. At present
there is no evidence that pregnancy affects the course of BOT.
However, it is not yet possible to provide guidelines for COH-
IVF in patients with advanced stage BOT despite successful
pregnancy outcomes (11-13, 19). In our study one patient
with stage IIIc disease, without invasive peritoneal implant,
had conservative treatment and underwent COH-IVF sub-
sequently that resulted in a successful pregnancy and deliv-
ery. There is no evidence of recurrence during the follow-up
period. It seems that the number of COH-IVF cycles should
be limited in patients with advanced stage BOT because
rapid progression to invasive ovarian cancer, after a success-
ful delivery with the first IVF cycle has been reported (20).
Although the pathogenic mechanisms for tumor progression
remain unknown, it may be related to hormonal influences
(9). Estrogen receptor expression was recently demonstrated
in BOT, and high serum E2 levels during COH-IVF may
have a role in tumor promotion (10).
After conservative treatment of BOT the recurrence rate
is estimated to be 0-20% (21). All recurrences can be detect-
ed with close follow-up. There is no significant difference in
survival rates between conservative and radical treatment
(22, 23). Beiner et al. reported a 29% recurrence rate in an
IVF treatment group that was not significantly different from
the 19% recurrence in the non-IVF group (16). Fasouliotis
et al. reported a 20% recurrence rate after IVF treatment.
All recurrences had a histology identical to the primary diag-
nosis; they were conservatively treated without evidence of
recurrence at the last follow-up (11). In our study, no recur-
rence of BOT was detected after COH-IVF; this is a lower
recurrence rate than reported in patients who underwent con-
servative treatment without subsequent fertility treatment.
Although the perod of 29.6 (14-61) months is not a long
follow-up period, our results suggest that COH-IVF may
*Elapsed time from initial BOT to recurrence; 
� Elapsed time from recur-
rence to the 1st IVF cycle.
BOT, borderline ovarian tumor; IVF, in vitro fertilization.
Patient
Time from
surgery
to 1st IVF (mo)
IVF cycles
Follow-up 
periods from
1st IVF (mo)
Recurrence
17 2 2 7 N o
2 108* - - Yes
19
� 21 5N o
35 4 6 1 N o
45 2 3 1 N o
5 21 1 14 No
Table 3. Recurrence of BOT after conservative treatmentS138 C.W. Park, K.M. Yang, H.O. Kim, et al.
not affect recurrence of BOT, and that pregnancy per se has
no effect on the course of BOT.
In conclusion, the current study suggests that IVF may be
considered for infertile patients after conservative treatment
for early stage BOT. For patients with advanced stage BOT,
larger clinical trials with longer follow-up are necessary to
evaluate the safety and efficacy of COH-IVF. All patients
should be informed of the potential risks associated with ovar-
ian hyperstimulation, and close follow-up is necessary after
COH-IVF. 
REFERENCES
1. Trope CG, Kristensen G, Makar A. Surgery for borderline tumor of
the ovary. Semin Surg Oncol 2000; 19: 69-75.
2. Kurman RJ, Trimble CL. The behavior of serous tumors of low ma-
lignant potential: are they ever malignant? Int J Gynecol Pathol
1993; 12: 120-7. 
3. Casey AC, Bell DA, Lage JM, Fuller AF, Nikrui N, Rice LW. Epi-
thelial ovarian tumors of borderline malignancy: long-term follow-
up. Gynecol Oncol 1993; 50: 316-22.
4. Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mos-
gaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH. Infertility,
fertility drugs, and ovarian cancer: a pooled analysis of case-con-
trol studies. Am J Epidemiol 2002; 155: 217-24.
5. Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG,
Human menopausal gonadotropin and the risk of epithelial ovarian
cancer. Fertil Steril 1996; 65: 13-8.
6. Harris R, Whittemore AS, Itnyre J. Characteristics relating to ovar-
ian cancer risk: collaborative analysis of 12 US case-control stud-
ies. III. Epithelial tumors of low malignant potential in white women.
Collaborative Ovarian Cancer Group. Am J Epidemiol 1992; 136:
1204-11.
7. Parazzini F, Negri E, La Vecchia C, Moroni S, Polatti A, Chiaffari-
no F. Treatment for fertility and risk of ovarian tumors of borderline
malignancy. Gynecol Oncol 1998; 68: 226-8.
8. Shushan A, Paltiel O, Schenker JG. Induction of ovulation and bor-
derline ovarian cancer--the hormonal connection? Eur J Obstet Gy-
necol Reprod Biol 1999; 85: 71-4.
9. Abu-Jawdeh GM, Jacobs TW, Niloff J, Cannistra SA. Estrogen re-
ceptor expression is a common feature of ovarian borderline tumors.
Gynecol Oncol 1996; 60: 301-7.
10. Madelenat P, Meneux E, Fernandez H, Uzan S, Antoine JM. Place
de l’assistance a la procreation apres traitement conservateur d’une
tumeur ovarienne: enquete multicentrique francaise. 10eme Congres
de la Societe Francaise d’Oncologie Gynecologique. Poitiers. France.
5-6 November 1999.
11. Fasouliotis SJ, Davis O, Schattman G, Spandorfer SD, Kligman I,
Rosenwaks Z. Safety and efficacy of infertility treatment after con-
servative management of borderline ovarian tumors: a preliminary
report. Fertil Steril 2004; 82: 568-72.
12. Nijman HW, Burger CW, Baak JP, Schats R, Vermorken JB, Kene-
mans P. Borderline malignancy of the ovary and controlled hyper-
stimulation, a report of 2 cases. Eur J Cancer 1992; 28: 1971-3.
13. Mantzavinos T, Kanakas N, Genatas C, Papadias K, Zourlas PA.
Five years’ follow-up in two patients with borderline tumours of the
ovary hyperstimulated by gonadotrophin therapy for in-vitro fertil-
ization. Hum Reprod 1994; 9: 2032-3.
14. Hoffman JS, Laird L, Benadiva C, Dreiss R. In vitro fertilization fol-
lowing conservative management of stage 3 serous borderline tumor
of the ovary. Gynecol Oncol 1999; 74: 515-8.
15. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian
tumors in a cohort of infertile women. N Engl J Med 1994; 331:
771-6. 
16. Beiner ME, Gotlieb WH, Davidson B, Kopolovic J, Ben-Baruch G.
Infertility treatment after conservative management of borderline
ovarian tumors. Cancer 2001; 92: 320-5.
17. Seidman JD, Kurman RJ. Subclassification of serous borderline tu-
mors of the ovary into benign and malignant types. A clinicopatho-
logic study of 65 advanced stage cases. Am J Surg Pathol 1996; 20:
1331-45. 
18. Camatte S, Morice P, Pautier P, Atallah D, Duvillard P, Castaigne D.
Fertility results after conservative treatment of advanced stage serous
borderline tumour of the ovary. BJOG 2002; 109: 376-80.
19. Attar E, Berkman S, Topuz S, Baysal B, Akhan S, Chambers JT.
Evolutive peritoneal disease after conservative management and the
use of infertility drugs in a patient with stage IIIC borderline micro-
papillary serous carcinoma (MPSC) of the ovary: case report. Hum
Reprod 2004; 19: 1472-5.
20. Morice P, Camatte S, Wickart-Poque F, Rouzier R, Pautier P, Pomel
C, Lhomme C, Haie-Meder C, Duvillard P, Castaigne D. Conserva-
tive management of malignant and borderline ovarian tumor. Bull
Cancer 2002; 89: 1019-26. 
21. Donnez J, Munschke A, Berliere M, Pirard C, Jadoul P, Smets M.
Safety of conservative management and fertility outcome in women
with borderline tumors of the ovary. Fertil Steril 2003; 79: 1216-21.
22. Seracchioli R, Venturoli S, Colombo FM, Govoni F, Missiroli S,
Bagnoli A. Fertility and tumor recurrence rate after conservative
laparoscopic management of young women with early-stage border-
line ovarian tumors. Fertil Steril 2001; 76: 999-1004.
23. Morris RT, Gershenson DM, Silva EG, Follen M, Morris M, Whar-
ton JT. Outcome and reproductive function after conservative sur-
gery for borderline ovarian tumors. Obstet Gynecol 2000; 95: 541-7.